文献速递类风湿关节炎

TARA试验两年成本效用分析:两种逐渐减量策略的成本效益对比

Two-year cost effectiveness between two gradual tapering strategies in rheumatoid arthritis: cost-utility analysis of the TARA trial.
PubMed 文献 · Ann Rheum Dis · 2020-09-09

基于TARA试验两年数据,比较类风湿关节炎患者先减量csDMARD再减量TNF抑制剂与相反顺序的成本效用。结果显示两种策略总成本相似,QALYs相近,成本效益相当,但成本效益概率受支付意愿阈值影响。

要点

  • 两种减量策略总成本差异无统计学意义(p=0.88)。
  • QALYs在两种策略间相近(1.64 vs 1.65)。

核心结论

  • 两种逐渐减量策略的成本相似,无论支付意愿如何,成本效益相当。

研究设计与样本

  • 基于TARA试验的两年数据,纳入使用csDMARD和TNF抑制剂且疾病控制良好(DAS≤2.4且肿胀关节计数≤1)至少3个月的RA患者,随机分为先减csDMARD后减TNF抑制剂或相反顺序。
  • 使用EQ-5D计算QALYs,从患者记录和问卷计算医疗保健和生产力成本,采用增量成本效果比和增量净货币效益评估成本效益。

主要发现

  • QALYs(标准差)分别为先减TNF抑制剂组1.64(0.22)和先减csDMARD组1.65(0.22)。
  • 先减TNF抑制剂组药物成本显著更低,但因生产力损失更多导致间接成本更高(p=0.10)。

临床怎么用

  • 临床决策中两种减量顺序均可考虑,成本效益相当,但需结合支付意愿阈值和患者个体情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of the current study was to evaluate the 2-year cost-utility ratio between tapering conventional synthetic disease-modifying antirheumatic drugs (csDMARD) first followed by the tumour necrosis factor (TNF)-inhibitor, or vice versa, in patients with rheumatoid arthritis (RA). METHODS: Two-year data of the Tapering strategies in Rheumatoid Arthritis trial were used. Patients with RA, who used both a csDMARD and a TNF-inhibitor and had a well-controlled disease (disease activity score ≤2.4 and swollen joint count≤1) for at least 3 months, were randomised into gradual tapering the csDMARD first followed by the TNF-inhibitor, or vice versa. Quality-adjusted life years (QALYs) were derived from the European Quality of life questionnaire with 5 dimensions. Healthcare and productivity costs were calculated with data from patient records and questionnaires. The incremental cost-effectiveness ratio and the incremental net monetary benefit were used to assess cost effectiveness between both tapering strategies. RESULTS: 94 patients started tapering their TNF-inhibitor first, while the other 95 tapered their csDMARD first. QALYs (SD) were, respectively, 1.64 (0.22) and 1.65 (0.22). Medication costs were significantly lower in the patients who tapered the TNF-inhibitor first, while indirect cost were higher due to more productivity loss (p=0.10). Therefore, total costs (SD) were €38 833 (€39 616) for tapering csDMARDs first, and €39 442 (€47 271) for tapering the TNF-inhibitor (p=0.88). For willingness-to-pay (WTP) levels <€83 800 tapering, the csDMARD first has the highest probability of being cost effective, while for WTP levels >€83 800 tapering the TNF-inhibitor first has the highest probability. CONCLUSION: Our economic evaluation shows that costs are similar for both tapering strategies. Regardless of the WTP, tapering either the TNF-inhibitor or the csDMARD first is equally cost effective. TRIAL REGISTRATION NUMBER: NTR2754.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. van Mulligen E, Weel AE, Kuijper TM, et al. Two-year cost effectiveness between two gradual tapering strategies in rheumatoid arthritis: cost-utility analysis of the TARA trial. Ann Rheum Dis. 2020. PMID: 32907801. doi:10.1136/annrheumdis-2020-217528

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。